Helex Secures $3.5m Funding for Kidney Disease Therapies
Helex has raised $3.5m in a seed funding round led by pi Ventures to advance non-viral gene therapies for kidney diseases.
The company is developing programmable non-viral LNP therapies to deliver therapeutic cargo to kidney cells.
- Participation from SOSV, Bluehill Capital, and a global investor syndicate
- Total funding exceeds $6m
Helex will use the funding to progress its autosomal dominant polycystic kidney disease (ADPKD) lead programme and expand its pipeline using AI-based drug design platforms and programmable delivery.
The funding will enable Helex to advance its non-viral gene therapies for kidney diseases.
Author's summary: Helex raises $3.5m for kidney disease therapies.
More News
- Kelly Vedovelli révèle sa vie amoureuse
- Kelly Massol : « J’ai réalisé 40% de mon ambition »
- Jay Kelly cast guide: All on which characters George Clooney, Adam Sandler and Laura Dern play in the film
- NBA: Spurs at Timberwolves
- How former Gonzaga stars perform in NBA
- How to watch Islanders vs. Lightning: TV channel and streaming options for December 6
- JUST IN: Kelly Olynyk has been waived by the San Antonio Spurs
- Islanders vs. Lightning (Dec 6, 2025) Pregame
- Guadeloupean artist Kelly Sinnapah Mary wins French art prize at Art Basel Miami Beach
- Hamilton urges Ferrari to make 'personnel changes' ahead of F1 2026